Drug Profile
Polycarboxylic fatty acid/selective estrogen receptor degrader - NovoLipid
Alternative Names: Polycarboxylic fatty acid/SERD; Polycarboxylic fatty acid/SERD conjugateLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer NovoLipid
- Class Drug conjugates; Fatty acids
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Solid-tumours(Second-line therapy or greater, Treatment-resistant) in USA (IV)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Solid-tumours(Second-line therapy or greater, Treatment-resistant) in USA (PO)